A CLINICAL AND MOLECULAR RISK-DIRECTED THERAPY FOR NEWLY DIAGNOSED MEDULLOBLASTOMA

Registry ID

SJMB12

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

ST JUDE CHILDRENS RESEARCH HOSPITAL

Start date

2019-06-11

Last update

2015-05-22

Conditions

• MEDULLOBLASTOMA

Related clinical trials

• A PHASE 3 STUDY OF SODIUM THIOSULFATE FOR REDUCTION OF CISPLATIN-INDUCED OTOTOXICITY IN CHILDREN WITH AVERAGE-RISK MEDULLOBLASTOMA AND REDUCED THERAPY IN CHILDREN WITH MEDULLOBLASTOMA WITH LOW-RISK FEATURES
• PHASE II TRIAL OF EFLORNITHINE/DFMO AS MAINTENANCE THERAPY FOR MOLECULAR HIGH RISK/VERY HIGH RISK AND RELAPSED/REFRACTORY MEDULLOBLASTOMA
• PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METFORMIN FOR COGNITIVE RECOVERY AND WHITE MATTER GROWTH IN PAEDIATRIC PATIENTS WITH A BRAIN TUMOUR
• A PHASE 2 STUDY OF REDUCED THERAPY FOR NEWLY DIAGNOSED AVERAGE-RISK WNT-DRIVEN MEDULLOBLASTOMA PATIENTS
• NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO EITHER SINGLE-CYCLE OR TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE

View on source registry